Tempus AI SEC Filings

Tempus AI, Inc. (TEM) filed a Form 144 notifying a proposed sale of 332,500 Class A common shares through J.P. Morgan Securities LLC with an aggregate market value of $27,973,225, to be sold on 09/25/2025 on Nasdaq. The filing lists the issuer and multiple acquisition lots for the shares, including stock compensation and direct investments dated between 2016 and 2024. The form also discloses several sales by related parties in the prior three months, including individual transactions on 07/28/2025, 08/19/2025, and 08/27/2025. The signer certifies no undisclosed material adverse information and references Rule 10b5-1 procedures if applicable.

Ryan Fukushima, Chief Operating Officer of Tempus AI, Inc. (TEM), reported multiple sales of Class A common stock on September 2, 2025. The Form 4 states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted March 4, 2025. The filing lists a series of dispositions executed at weighted-average prices ranging from about $72.40 to $78.30, with specific weighted-average prices reported for groups of trades (for example, $72.73, $74.00, $74.95, $76.03, $76.77, $78.06). The reported entries show shares sold on that date and indicate indirect beneficial ownership through the reporting person’s spouse and an irrevocable family trust. The Form is signed by an attorney-in-fact on behalf of the reporting person.

Tempus AI director David R. Epstein reported a sale of 250 shares of Class A common stock on 09/02/2025 at $73.64 per share. The Form 4 shows the transaction was executed under a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2024. After the reported sale, Epstein beneficially owned 27,041 shares, held directly. The filing was submitted by one reporting person and signed by an attorney-in-fact on 09/04/2025.

Tempus AI insider sales by Eric P. Lefkofsky completed under a Rule 10b5-1 plan. On 08/27/2025 Lefkofsky (CEO and Chairman) reported multiple open-market dispositions of Class A common stock executed pursuant to a March 4, 2025 10b5-1 trading plan. Reported sales occurred at weighted-average prices in four price ranges: $72.21–$73.20, $73.21–$74.20, $74.21–$75.20 and $75.21–$75.83, with specific weighted-average prices listed as $72.89, $73.81, $74.59 and $75.47.

Transactions on that date include a series of sales totaling several hundred thousand shares across entities he controls, with reported beneficial ownership balances after the sales listed for multiple entities (for example, 9,207,533, 17,869,469, and 18,110,360 shares for certain entities) and additional holdings such as 10,000,000 shares held in the Lefkofsky Family 2025 GRAT. The Form 4 is signed by an attorney-in-fact and includes explanations of grouping and pricing detail.

Theodore Leonsis, a director of Tempus AI, Inc. (TEM), reported the sale of Class A common stock on 08/26/2025. The Form 4 shows 20,000 shares were sold at a weighted average price of $75.83, with individual trade prices reported in a range from $75.72 to $76.00. After the reported transactions, the filing lists 66,756 shares beneficially owned indirectly through the Theodore J. Leonsis Revocable Trust and 15,511 shares beneficially owned directly. The Form 4 was signed by an attorney-in-fact on 08/28/2025 and includes a footnote offering to provide a breakdown of shares sold at each price within the stated range.

Tempus AI, Inc. discloses that 125,404 shares of Class A common stock were issued under a Settlement and Release Agreement among MSK, Paige.AI and Tempus relating to intellectual property licensing and mutual claims releases. The prospectus supplement includes tables listing multiple selling stockholders with pre- and post-offering beneficial ownership figures, including several entries showing holdings in the low thousands to millions and asterisks for percentages deemed de minimis. The company describes three product lines: Genomics (sequencing and de-identified data commercialized as Insights and Trials), Data and Services, and AI Applications (diagnostics and clinical decision support). Based on market value as of June 30, 2025, Tempus expects to become a large accelerated filer and cease qualifying as an emerging growth company as of December 31, 2025.

Tempus AI, Inc. (TEM) filed a Form 144 notice showing an intended sale of 332,500 Class A common shares via J.P. Morgan Securities on 08/27/2025 listed on Nasdaq with an aggregate market value of $25,236,750. The filing discloses acquisition lots: 41,401; 103,897; 109,943; 10,759 shares all received as stock compensation in February 2025, and a 66,500-share direct cash purchase from September 14, 2017. The filing also lists multiple Class A sales in the prior three months by Eric Lefkofsky, Blue Media, LLC and Gray Media, LLC with gross proceeds shown per sale.

Form 144 summary: The filing notifies a proposed sale of 20,000 shares of common stock of the issuer, with an aggregate market value of $1,516,650, expected to be sold on 08/26/2025 through Citigroup Global Markets Inc. The securities were acquired on 01/30/2025 as a venture capital distribution from Revolution Growth III, comprising 130,756 shares received and paid on that date. The issuer has 168,683,769 shares outstanding per the form. The filing also reports a prior sale in the past three months: Theodore Leonsis sold 44,000 shares on 08/13/2025 for $3,075,786.12. The signer certifies they are unaware of undisclosed material adverse information.